Genetic and molecular alterations, such as TP53 mutations, have been frequently identified in aggressive HCC cases and are connected to poor prognosis, while CTNNB1 (β-catenin) mutations are coupled with better outcomes but also resistance to immune checkpoint inhibitors [31]. The gene discussed is CTNNB1; the disease is hepatocellular carcinoma.